Proven leader in commercializing organ-on-a-chip platforms from concept to multi-million-dollar businesses Follows validation datasets published by leading pharmaceutical companies1,2,3 NEW […]
NEW ORLEANS, La. (June 11, 2024)—AxoSim, a life science company building human brains in the lab at scale to heal
AxoSim Appoints Alif Saleh as Chief Executive Officer to Drive Market Adoption Read more
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors —Serial Entrepreneurs Dale Pfost and David Weiner
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors Read more
New Orleans, La. ─ October 24, 2023 ─ AxoSim, Inc., a leader in the development and application of live biomimetic human drug discovery
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio’s StemoniX Assets —Combines Three Leading Human Biomimetic Organoid Platform Technologies
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio’s StemoniX Assets Read more
BENSON CAPITAL PARTNERS ANNOUNCES FIRST INVESTMENT IN AXOSIM, INC. AxoSim, Inc, Provider of BrainSimâ„¢ and NerveSimâ„¢ Neurological Drug Discovery Platforms
Benson Capital Partners Announces First Investment in AxoSim Read more
–Two grants from the DoD Congressionally Directed Medical Research Program and the National Institutes of Health awarded to AxoSim–Â –The
AxoSim Announces the Award of over $870,000 in Federal Grants Read more
